The LiBBY trial studied 120 people with late-stage dementia and strong agitation who qualified for hospice care, not their spouses or partners. For spouses and partners, the findings describe a patient treatment result, not a caregiver treatment.
LiBBY stands for Life's End Benefits of cannabidiol and tetrahydrocannabinol. Agitation means restlessness, aggression, or distress that disrupts care. Topline Phase 2 results were first reported July 14, 2026, at AAIC in London, according to the Alzheimer's Association in the AAIC topline release.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who qualified for LiBBY?
- What treatment was tested?
- How much changed by Week 12?
- Who was not studied?
- What should caregiving spouses do next?
Who qualified for LiBBY?
Participants had Alzheimer's disease or another dementia with clinically significant agitation. They were eligible for or receiving hospice care. Study visits took place in homes or residences across U.S.
sites. Participants averaged about 80 years old, and 55% were female. About 58% were from underrepresented ethnoracial groups. About 75% lived in community settings rather than institutions.
What treatment was tested?
Active treatment was a novel oral oil with 2 mg THC plus 100 mg CBD in digestible oil. It was given twice daily, according to the Pennington Biomedical Research Center in the Pennington trial details. THC is the intoxicating part of cannabis, while CBD is non-intoxicating.
Benefit appeared early. By Week 2, THC and CBD recipients had a 6.27-point larger drop in Cohen-Mansfield Agitation Inventory scores than placebo recipients, according to the Georgetown University School of Medicine in the Georgetown trial summary. That inventory is a standard scale that rates agitation behaviors.
How much changed by Week 12?
By Week 12, nearly 9 in 10 people who received THC and CBD showed overall improvement in target agitation symptoms. The result points to lower frequency or intensity of the behaviors that disturb rest and care.
For a spouse at home, that could mean fewer episodes of shouting, pacing, or resisting help. It does not mean improved memory or reversal of dementia. The trial measured agitation, not cognition or daily independence.
Who was not studied?
LiBBY did not treat spouses or partners themselves. It also did not include several groups spouses may ask about: That gap matters for decisions.
A partner with new forgetfulness, mild impairment, or agitation earlier in illness was outside this study. Findings from hospice-eligible late-stage patients do not transfer directly to those situations.
- people with early-stage dementia
- people with mild memory concerns without agitation
- patients who are not eligible for hospice care
What should caregiving spouses do next?
LiBBY was a small 12-week Phase 2 topline trial. It does not establish routine cannabis use or dispensary products for agitation.
Dose, purity, and supervision differed from retail cannabis. Spouses should bring agitation logs, current drugs, fall history, and hospice goals to the care team. Ask whether cannabinoids fit, what risks apply, and what supervision is needed before considering them.
You Might Also Like
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: Who Was Studied and Who Was Not for Spouses and Partners
- Dementia Subtype Data Gaps Identified by NIA in 2026: Why the Findings May Not Change Care Yet for Adults With Memory Concerns
- LatAm-FINGERS Lifestyle Coaching Findings Across 11 Countries in 2026: How Adult Children Can Build a Realistic Brain Health Plan
